{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T14:37:26Z","timestamp":1772807846237,"version":"3.50.1"},"reference-count":34,"publisher":"XMLink","issue":"3","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ejgo.org"],"crossmark-restriction":false},"short-container-title":["J Gynecol Oncol"],"DOI":"10.3802\/jgo.2025.36.e36","type":"journal-article","created":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T05:22:32Z","timestamp":1728364952000},"update-policy":"https:\/\/doi.org\/10.3802\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Bevacizumab combined with chemotherapy could be superior to chemotherapy alone in relapsed ovarian cancer after PARPi: evidence from a multi-center propensity score-matched analysis"],"prefix":"10.3802","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9224-9537","authenticated-orcid":false,"given":"Lin","family":"Zhong","sequence":"first","affiliation":[{"name":"Department of Gynecologic Oncology, Chongqing University Cancer Hospital & Chongqing Cancer Institute & Chongqing Cancer Hospital, Chongqing, China."},{"name":"Chongqing Specialized Medical Research Center of Ovarian Cancer, Chongqing, China."},{"name":"Organoid Transformational Research Center, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4847-1421","authenticated-orcid":false,"given":"Haixia","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Chongqing University Cancer Hospital & Chongqing Cancer Institute & Chongqing Cancer Hospital, Chongqing, China."},{"name":"Chongqing Specialized Medical Research Center of Ovarian Cancer, Chongqing, China."},{"name":"Organoid Transformational Research Center, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4256-2855","authenticated-orcid":false,"given":"Cuirong","family":"Lei","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Chongqing University Cancer Hospital & Chongqing Cancer Institute & Chongqing Cancer Hospital, Chongqing, China."},{"name":"Chongqing Specialized Medical Research Center of Ovarian Cancer, Chongqing, China."},{"name":"Organoid Transformational Research Center, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9158-8783","authenticated-orcid":false,"given":"Dongling","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Chongqing University Cancer Hospital & Chongqing Cancer Institute & Chongqing Cancer Hospital, Chongqing, China."},{"name":"Chongqing Specialized Medical Research Center of Ovarian Cancer, Chongqing, China."},{"name":"Organoid Transformational Research Center, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18617","published-online":{"date-parts":[[2025]]},"reference":[{"key":"10.3802\/jgo.2025.36.e36_ref1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.3802\/jgo.2025.36.e36_ref2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","volume":"361","author":"Fong","year":"2009","journal-title":"N Engl J Med"},{"key":"10.3802\/jgo.2025.36.e36_ref3","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1200\/JCO.22.01549","volume":"41","author":"DiSilvestro","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.3802\/jgo.2025.36.e36_ref4","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.annonc.2022.06.011","volume":"33","author":"Frenel","year":"2022","journal-title":"Ann Oncol"},{"key":"10.3802\/jgo.2025.36.e36_ref5","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1097\/CAD.0000000000001219","volume":"32","author":"Rose","year":"2021","journal-title":"Anticancer Drugs"},{"key":"10.3802\/jgo.2025.36.e36_ref6","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ygyno.2022.02.002","volume":"165","author":"Park","year":"2022","journal-title":"Gynecol Oncol"},{"key":"10.3802\/jgo.2025.36.e36_ref7","unstructured":"GlaxoSmithKline. Important prescribing information: subject: Zejula (niraparib) important prescribing information for the maintenance treatment of adult patients with non-gBRCAmut recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy in second or later line setting [Internet]. Brentford. GlaxoSmithKline. 2022. cited 2023 Aug 4. Available from: https:\/\/medinfo.gsk.com\/5f95dbd7-245e-4e65-9f36-1a99e28e5bba\/c1ecd517-3f83-46c1-941c-9a1072b132a9\/c1ecd517-3f83-46c1-941c-9a1072b132a9_viewable_rendition__v.pdf?medcommid=REF--US-001267"},{"key":"10.3802\/jgo.2025.36.e36_ref8","first-page":"A3","volume":"32","author":"Coleman","year":"2022","journal-title":"Int J Gynecol Cancer"},{"key":"10.3802\/jgo.2025.36.e36_ref9","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.3390\/cancers12061607","volume":"12","author":"McMullen","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.3802\/jgo.2025.36.e36_ref10","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1200\/JCO.2009.26.9589","volume":"28","author":"Fong","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.3802\/jgo.2025.36.e36_ref11","doi-asserted-by":"crossref","first-page":"5517","DOI":"10.1200\/JCO.2021.39.15_suppl.5517","volume":"39","author":"Oza","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.3802\/jgo.2025.36.e36_ref12","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231157644","volume":"15","author":"Veneziani","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"10.3802\/jgo.2025.36.e36_ref13","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.ygyno.2021.05.018","volume":"162","author":"Alvarez Secord","year":"2021","journal-title":"Gynecol Oncol"},{"key":"10.3802\/jgo.2025.36.e36_ref14","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.3802\/jgo.2025.36.e36_ref15","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","volume":"18","author":"Coleman","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.3802\/jgo.2025.36.e36_ref16","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.3802\/jgo.2025.36.e36_ref17","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.3802\/jgo.2025.36.e36_ref18","unstructured":"National Cancer Institute of the National Institutes of Health (US). Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 [Internet]. Bethesda, MD. National Cancer Institute. Published 2009. cited 2024 May 5. Available from: https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/Archive\/CTCAE_4.0_2009-05-29_QuickReference_8.5x11.pdf"},{"key":"10.3802\/jgo.2025.36.e36_ref19","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S1470-2045(20)30142-X","volume":"21","author":"Pfisterer","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.3802\/jgo.2025.36.e36_ref20","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature04483","volume":"438","author":"Ferrara","year":"2005","journal-title":"Nature"},{"key":"10.3802\/jgo.2025.36.e36_ref21","doi-asserted-by":"crossref","first-page":"8206","DOI":"10.7150\/thno.37455","volume":"9","author":"He","year":"2019","journal-title":"Theranostics"},{"key":"10.3802\/jgo.2025.36.e36_ref22","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.mvr.2007.05.003","volume":"74","author":"Fukumura","year":"2007","journal-title":"Microvasc Res"},{"key":"10.3802\/jgo.2025.36.e36_ref23","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ccell.2014.10.006","volume":"26","author":"Jain","year":"2014","journal-title":"Cancer Cell"},{"key":"10.3802\/jgo.2025.36.e36_ref24","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.neo.2014.04.003","volume":"16","author":"Lim","year":"2014","journal-title":"Neoplasia"},{"key":"10.3802\/jgo.2025.36.e36_ref25","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.semcancer.2023.11.007","volume":"98","author":"Altwerger","year":"2024","journal-title":"Semin Cancer Biol"},{"key":"10.3802\/jgo.2025.36.e36_ref26","doi-asserted-by":"crossref","first-page":"4206","DOI":"10.1158\/1078-0432.CCR-19-4121","volume":"26","author":"Lheureux","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.3802\/jgo.2025.36.e36_ref27","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.3802\/jgo.2022.33.e12","volume":"33","author":"Park","year":"2022","journal-title":"J Gynecol Oncol"},{"key":"10.3802\/jgo.2025.36.e36_ref28","unstructured":"Peking Union Medical College Hospital. A phase II trial to explore niraparib and anlotinib maintenance retreatment in platinum-sensitive recurrent ovarian cancer patients previously treated with PARPi (t) [Internet]. Bethesda, MD. National Library of Medicine. 2022. cited 2024 May 9. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05385068"},{"key":"10.3802\/jgo.2025.36.e36_ref29","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ygyno.2016.05.017","volume":"142","author":"Petrillo","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.3802\/jgo.2025.36.e36_ref30","doi-asserted-by":"crossref","first-page":"e2326834","DOI":"10.1001\/jamanetworkopen.2023.26834","volume":"6","author":"Takamatsu","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.3802\/jgo.2025.36.e36_ref31","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s00384-023-04442-5","volume":"38","author":"Deng","year":"2023","journal-title":"Int J Colorectal Dis"},{"key":"10.3802\/jgo.2025.36.e36_ref32","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","volume":"365","author":"Perren","year":"2011","journal-title":"N Engl J Med"},{"key":"10.3802\/jgo.2025.36.e36_ref33","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa2103294","volume":"385","author":"Harter","year":"2021","journal-title":"N Engl J Med"},{"key":"10.3802\/jgo.2025.36.e36_ref34","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1136\/ijgc-2022-003435","volume":"32","author":"Schettino","year":"2022","journal-title":"Int J Gynecol Cancer"}],"container-title":["Journal of Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ejgo.org\/pdf\/10.3802\/jgo.2025.36.e36","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ejgo.org\/DOIx.php?id=10.3802\/jgo.2025.36.e36","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ejgo.org\/DOIx.php?id=10.3802\/jgo.2025.36.e36","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T01:54:31Z","timestamp":1747360471000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejgo.org\/DOIx.php?id=10.3802\/jgo.2025.36.e36"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.3802\/jgo.2025.36.e36","relation":{},"ISSN":["2005-0380","2005-0399"],"issn-type":[{"value":"2005-0380","type":"print"},{"value":"2005-0399","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"2024-03-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-07","name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-28","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-07","name":"published_online","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"\u00a9 2025. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology","name":"copyright","label":"Copyright","group":{"name":"Copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.","name":"license","label":"License","explanation":{"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},"group":{"name":"Copyright_and_licensing","label":"Copyright and Licensing"}}],"article-number":"e36"}}